Details
Category: Volume 05 Issue 07 July 2017
Hits: 1200

Title: Feasibility of Weekly Cisplatin Versus Gemcitabine Concomitant with Radiation in The Management of Locally Advanced Carcinoma Cervix

Authors: Vani Singh, S K Singh, J K Singh, Bhaskar Shahbabu, Richa Chauhan, Anamika Kumari

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i7.235

Abstract

Introduction: Cervical cancer is the fourth most common malignancy in women worldwide (1). The study was conducted to evaluate the feasibility, toxicity and response of weekly gemcitabine against the widely accepted weekly cisplatin with concurrent conventional radiotherapy in management of locally advanced cervical cancer.

Methodology: A prospective randomized control study was done with 25 patients of carcinoma cervix in each arm of Gemcitabine (Group A) and Cisplatin (Group B) based concurrent chemoradiotherapy. Pre-treatment and Post-treatment assessment was done to assess the efficacy and toxicity profile of the patients.

Results: External beam radiation as per protocol was completed by 60% in Group A and 68% in Group B. 52% patients in group A and 60% in group B completed the treatment in less than 55 days. Acute toxicities were responsible for 20% of the delay in-group A and 16% of group B. Late toxicities were mild to moderate. Overall complete response was seen in 83.3% of patients in-group A and 80% patients in-group B. Locoregional control was seen in 79.2% of the patients of group A and 76% of patients of group B. Locoregional failure was seen in 12.5% patients of group A and 12% patients of group B. 4.17% patients in group A and 8% patients in group B had distant metastases.

Conclusion: Gemcitabine can be a better alternative to Cisplatin considering its easy administration, similar disease control and toxicity profile.

Keywords: Cervical Cancer, Gemcitabine, Cisplatin, Chemoradiotherapy,

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide.
  2. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in India 2007. Available from: http://www.who.int/hpvcentre.  
  3. Miller AB: Cervical cancer screening programmes: managerial guidelines. Geneva: World Health Organisation; 1992.
  4. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144-1153.
  5. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV,Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J ClinOncol. 1999; 17:1339-1348.
  6. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. SeminOncol.1997; 24:24-28.
  7. Hernández P, Olivera P, Dueñas-Gonzalez A, Perez-Pastenes MA, Zarate A, Maldonado V, et al. Gemcitabine activity in cervical cancer cell lines. Cancer Chemother Pharmacol 2001; 48:488-492.
  8. Pattaranutaporn P, Thirapakawong C, Chansilpa Y, Thersakvivhya S, Ieumwananontachai N, Thephamongkhol K. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma.GynecolOncol. 2001;81:404-407.
  9. Bhatt ML, Matin A, Srivastava M, Pant MC, Srivastava K,Gupta S, et al . Journal of Clinical oncology. 2007 ASCO Annual Meeting proceedings part I Vol .
  10. Devita, Hellman, and Rosenberg’s Cancer Principles and Practice of oncology.Wolter Kluwer; 9th ed. 2011:1315 .
  11. Anthony Fauci., Eugene Braunwald., Dennis Kasper., Stephen Hauser., Dan Longo., J. Jameson. et al. Harrison's principles of internal medicine. McGraw-Hill Education; Vol 2, 19th ed. 2016:472
  12. Cooperative Group Common Toxicity Criteria [Internet]. Rtog.org. 2017 [cited 4 June 2017]. Available from: https://www.rtog.org/ResearchAssociates/AdverseEventReporting/CooperativeGroupCommonToxicityCriteria.aspx
  13. RTOG/EORTC Late Radiation Morbidity Scoring Schema [Internet]. Rtog.org. 2017 [cited 4 June 2017]. Available from: https://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiationMorbidityScoringSchema.aspx
  14. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009;45(2):228-247.
  15. Verma AK, Arya AK, Kumar M, Kumar A, Gupta S, RathG.k. et al. Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study. J GynecolOncol. Dec.2009; 20[4]:221-226.
  16. Rose PG, Ali S, WhitneyCW, Lanciano R, Stehman FB. Outcome of stage IVA cervical cancer patients with disease limited to pelvis in the era of chemoradiation.Gynecooncol 2011;121:542-45.
  17. Kundu S, Basu S, Acharya, S, Dastidar AG, Roy A. Chemoradiation in Locally advanced cervical cancer : a randomized trial. Indian J of Med &PediaOncol. 2008; 29(4).
  18. Elantholi P. Saibishkumar, Firuza D. Patel, Suresh C. Sharma .  Results of a phase II trial of concurrent chemoradiation in the treatment of locally advanced carcinoma of uterine cervix: an experience from India. Bull Cancer. 2005 ; 92 (1) : E7-12.
  19. HareyamaH,SakataK,OouchiA,NagakuraH,ShidoM,Someya M. High-Dose-Rate versus Low-Dose-Rate Intracavitary Therapy For Carcinoma of the Uterine Cervix.Cancer; 94:117-124.
  20. Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt MLB, Srivastava K. concurrent chomoradiotherapy for locally advanced cervical cancer using Gemcitabine : non randomized comparison of three sequential protocols. Cancer Therapy. 2007;5:43-54.
  21. Cetina L, Rivera L, Candelaria M, de la Garza J, Duenas-Gonzalez A. Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs2004; 15:761-766.

Corresponding Author

Santosh Kumar Singh

Lt Col. (Classified Specialist Internal Medicine),

Dept of Medicine and Pulmonary Medicine, MH Namkum, India

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.